ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Caribou Biosciences Inc

Caribou Biosciences Inc (CRBU)

1.75
-0.04
(-2.23%)
Closed June 17 4:00PM
1.79
0.04
( 2.29% )
Pre Market: 8:33AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.79
Bid
1.79
Ask
1.80
Volume
2,192
0.00 Day's Range 0.00
1.685 52 Week Range 8.5899
Market Cap
Previous Close
1.75
Open
-
Last Trade
16
@
1.79
Last Trade Time
08:33:25
Financial Volume
-
VWAP
-
Average Volume (3m)
2,222,628
Shares Outstanding
90,314,501
Dividend Yield
-
PE Ratio
-1.55
Earnings Per Share (EPS)
-1.13
Revenue
34.48M
Net Profit
-102.07M

About Caribou Biosciences Inc

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Dover, Delaware, USA
Founded
1970
Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was $1.75. Over the last year, Caribou Biosciences shares have traded in a share price range of $ 1.685 to $ 8.5899.

Caribou Biosciences currently has 90,314,501 shares outstanding. The market capitalization of Caribou Biosciences is $158.05 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -1.55.

CRBU Latest News

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in...

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into...

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.09-4.787234042551.882.121.68533345861.86789171CS
4-1.34-42.81150159743.133.191.68530603782.29175589CS
12-3.56-66.54205607485.355.51.68522226283.19784832CS
26-4.36-70.89430894316.158.331.68519105674.52035883CS
52-2.56-58.85057471264.358.58991.68522149995.24563763CS
156-15.86-89.858356940517.6532.6451.68511910707.44318673CS
260-15.86-89.858356940517.6532.6451.68511910707.44318673CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NLSPNLS Pharmaceutics Ltd
$ 0.3851
(159.68%)
95.58M
ASNSActelis Networks Inc
$ 2.73
(137.39%)
18.15M
RELIReliance Global Group Inc
$ 0.49
(120.72%)
4.97M
SNOASonoma Pharmaceuticals Inc
$ 0.2788
(65.46%)
40.16M
MLGOMicroAlgo Inc
$ 5.11
(43.94%)
7.39M
STISolidion Technology Inc
$ 0.5491
(-71.55%)
2.7M
DMTKDermTech Inc
$ 0.1371
(-58.77%)
705.39k
AWINAERWINS Technologies Inc
$ 1.51
(-54.79%)
79.34k
BIOLBiolase Inc
$ 0.0868
(-41.59%)
7.22M
QMCOQuantum Corporation
$ 0.4799
(-38.47%)
170.57k
NLSPNLS Pharmaceutics Ltd
$ 0.3851
(159.68%)
95.58M
MBIOMustang Bio Inc
$ 1.07
(42.67%)
41.58M
SNOASonoma Pharmaceuticals Inc
$ 0.2788
(65.46%)
40.16M
ASNSActelis Networks Inc
$ 2.73
(137.39%)
18.15M
QLGNQualigen Therapeutics Inc
$ 0.226
(29.29%)
16.36M

CRBU Discussion

View Posts
NY1972 NY1972 3 days ago
Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase
👍️0
Diego Rivas Diego Rivas 2 weeks ago
Any good news in here comming?
👍️0
jondoeuk jondoeuk 2 weeks ago
Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.
👍️0
jondoeuk jondoeuk 2 weeks ago
The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

* CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.
👍️0
Monksdream Monksdream 2 weeks ago
CRBU new 52 week low
👍️0
stocksrising stocksrising 2 weeks ago
Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…
👍️0
jondoeuk jondoeuk 2 weeks ago
It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.
👍️ 1
Monksdream Monksdream 4 weeks ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 1 month ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 2 months ago
CRBU under $5
👍️0
stocksrising stocksrising 3 months ago
It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
👍️0
Monksdream Monksdream 8 months ago
CRBU new 52 week low
👍️0
jondoeuk jondoeuk 11 months ago
Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.
👍️0
trueblue trueblue 11 months ago
.
👍️0
trueblue trueblue 11 months ago
$23.00 price target! Now that is a good start!! Glad I loaded up! Jmo
👍️0
NY1972 NY1972 11 months ago
Didn't they buy TRIL? Just gambling with billions from US government.
👍️0
jondoeuk jondoeuk 11 months ago
PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html
👍️0
trueblue trueblue 11 months ago
Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
👍️0
Monksdream Monksdream 11 months ago
CRBU now No 9 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
trueblue trueblue 11 months ago
Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo
👍️0
Stockexpertpro Stockexpertpro 11 months ago
CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/
👍️0
TheFinalCD TheFinalCD 11 months ago
CRBU= JUST WOW

https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d
👍️0
Monksdream Monksdream 11 months ago
CRBU No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Your Recent History

Delayed Upgrade Clock